trending Market Intelligence /marketintelligence/en/news-insights/trending/USEVCpN7LKVBNVPUlzLUWQ2 content esgSubNav
In This List

UCB's psoriasis drug Cimzia meets endpoint in final phase 3 trial

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


UCB's psoriasis drug Cimzia meets endpoint in final phase 3 trial

UCB SA's psoriasis drug Cimzia met the primary and several secondary endpoints in its third and final phase 3 trial.

The CIMPACT trial confirmed the safety and efficacy findings from the previous phase 3 trials. Patients with moderate-to-severe chronic plaque psoriasis showed 75% or greater disease improvement from baseline when treated with Cimzia, as compared with placebo.

Plaque psoriasis is the most common form of the psoriasis family of skin diseases and appears as raised, red patches covered with a silvery white buildup of dead skin cells.

The drug is being co-developed by UCB and Dermira Inc. as part of an agreement in July 2014. Dermira has exclusive rights to develop Cimzia for psoriasis in the U.S., Canada and the EU, and an exclusive commercial license to market the drug to dermatologists in the U.S. and Canada, subject to regulatory approval.

The companies expect to submit the drug for regulatory approvals in the third quarter of 2017.